Watch a Video

Learn more about our clinical trial in ET or PV
Play now

 
 

Imetelstat in Patients With Essential Thrombocythemia

This study has closed to patient enrollment


Helpful Information

  • Hematologic response is a decrease or normalization of platelets (ET) or red blood cells (PV) after treatment.
  • Molecular response rate is the percentage of patients who have a reduction in the percentage of mutant JAK2 or MPL alleles detected in their blood cells.

A Phase 2 Trial to Evaluate the Activity of Imetelstat (GRN163L) in Patients With Essential Thrombocythemia or Polycythemia Vera Who Require Cytoreduction and Have Failed or Are Intolerant to Previous Therapy, or Who Refuse Standard Therapy

Geron enrolled patients in a clinical trial to evaluate the potential activity of our product candidate, imetelstat, in patients with essential thrombocythemia (ET) or polycythemia vera (PV). This study was open to patients who had failed or were intolerant to at least one prior therapy, or who refused standard therapy.

In this Phase 2 clinical trial, our clinical researchers and investigators studied how imetelstat may affect the hematologic response in patients who have not responded to, or have not been able to tolerate, at least one other treatment, or who have refused standard therapy.

The study was also measuring the length of time patients respond to the treatment from the first dose through up to 36 months. In patients who have a mutation in the JAK2 or MPL genes, data were collected to evaluate the rate of molecular response. Learn about the preliminary results from this trial.

Imetelstat is an investigational treatment for cancer in development by Geron and has not been approved by the FDA or any other regulatory agency.

To learn more about this clinical trial, please visit ClinicalTrials.gov for the full trial summary and enrollment criteria.

About Imetelstat

Imetelstat inhibits the activity of telomerase, which is an enzyme present in most types of cancer that enables tumor cells to replicate indefinitely. Geron's potential anti-cancer strategy is to stop or slow down the growth and spread of tumors by inhibiting telomerase activity. Learn more

Cancer Definitions

To learn more about the terms and definitions used in cancer clinical studies you may find the National Cancer Institute Dictionary of Cancer Terms a useful resource.

Para obtener más información acerca de los términos y las definiciones utilizadas en los estudios clínicos sobre el cáncer es posible que el Instituto Nacional del Cáncer Diccionario de cáncer en un recurso útil.

Watch a Video

Learn more about our clinical trial in ET or PV
Play now

Close
Form content here please :)